Roivant Sciences (NASDAQ:ROIV) Director Daniel Allen Gold Sells 625,783 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Daniel Allen Gold sold 625,783 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $34.00, for a total value of $21,276,622.00. Following the sale, the director owned 14,501,546 shares of the company’s stock, valued at $493,052,564. This trade represents a 4.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Daniel Allen Gold also recently made the following trade(s):

• On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total transaction of $436,766.40.
• On Monday, June 29th, Daniel Allen Gold sold 800,000 shares of Roivant Sciences stock. The stock was sold at an average price of $34.55, for a total transaction of $27,640,000.00.

Roivant Sciences Trading Up 1.9%

Shares of ROIV traded up $0.66 on Tuesday, reaching $35.39. 6,160,114 shares of the company’s stock traded hands, compared to its average volume of 5,917,255. The stock’s 50 day simple moving average is $29.88 and its two-hundred day simple moving average is $27.02. The stock has a market cap of $25.45 billion, a PE ratio of -58.98 and a beta of 1.13. Roivant Sciences Ltd. has a 52-week low of $10.70 and a 52-week high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Wednesday, May 20th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.57. The firm had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period last year, the firm posted ($0.29) EPS. Analysts forecast that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Guggenheim raised their target price on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Citigroup upped their price objective on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $33.59.

Institutional Trading of Roivant Sciences

Large investors have recently modified their holdings of the business. SBI Securities Co. Ltd. grew its stake in Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Kestra Advisory Services LLC purchased a new position in shares of Roivant Sciences during the fourth quarter worth approximately $47,000. Parallel Advisors LLC raised its position in Roivant Sciences by 33.7% in the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC raised its position in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after purchasing an additional 2,665 shares during the period. Institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.